Skip to content

Author

M. Morfouace

We have 3 of 21 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

Understanding tumor adaptations and resistance to MET inhibitors in MET-altered non-small cell lung cancer

Highlights • MET inhibitor resistance is heterogeneous across distinct MET-altered NSCLC.• Spatial transcriptomics reveal shared ECM remodeling in tumors upon progression.• In vitro models partially recapitulate aspects of clinical MET inhibitor resistance.• CRISPR and combination drug screens reveal overlapping functi...

M. Simard, E. Marin, S. García-Román et al. · 0 citations
Open access Sep 2026

A multi-omics analysis of advanced triple-negative breast cancer identifies predictors to chemo-immunotherapy and on-treatment dynamics.

F fibrovascular and myeloid reprogramming is establish fibrovascular and myeloid reprogramming as a coordinated resistance program, identify actionable therapeutic targets, and support microenvironment stratification in future ICI-based trials.

N. Van Renne, E. Agostinetto, Andrea Joaquín-García et al. · 0 citations
Open access Sep 2026

Modelling interpretable patient-level representations from structured and simple multimodal data

FACTMx couples latent patient factors with subobservation clustering and per-patient component proportions, enabling direct interpretation and downstream association analyses, and supports joint structured-simple modelling for interpretable multimodal patient stratification.

Kazimierz Oksza-Orzechowski, Małgorzata Łazȩcka, Ł. Koperski et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.